Oleamide for Health & Longevity

Evidence Review created on 07/28/2026 using AI4L / Opus 4.8

Also known as: cis-9-octadecenoamide, (9Z)-octadec-9-enamide, 9-octadecenamide, oleic acid amide, ODA

Motivation

Oleamide is a fatty molecule the body makes on its own, built from oleic acid, the same fat that dominates olive oil. It was first noticed collecting in the fluid around the brain of animals kept awake, where it appeared to help tip the brain toward sleep. For this reason oleamide is often described as one of the body’s own sleep signals, and it is now sold as a supplement for people who want deeper, more natural rest.

The same molecule turns up in surprising places: aged cheeses, jujube fruit used in traditional remedies for centuries, and even as a slippery coating on some plastics. In the brain it does not act on a single target but nudges several calming and mood-related systems at once, which is part of what makes it interesting and also hard to pin down. A recent small study in older adults reported gains in memory and sleep-related measures after daily use.

This review examines what is known about oleamide as it relates to sleep, memory, and long-term brain health, separating where the evidence is genuinely supportive from where it rests only on animal work and where important safety questions remain open.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Oleamide

Grokipedia hosts a dedicated encyclopedia entry describing oleamide’s chemistry as an endogenous unsaturated primary fatty acid amide derived from oleic acid, its sleep and signaling roles, and its industrial uses. It provides a broad, referenced overview suitable for a general reader.

Examine

No dedicated Examine.com article exists for oleamide. Oleamide is a niche compound that is not currently included in Examine.com’s supplement database.

ConsumerLab

No dedicated ConsumerLab.com review or test report exists for oleamide. ConsumerLab has not published independent testing of oleamide supplements as of the date of this review.

Systematic Reviews

No systematic reviews or meta-analyses for Oleamide were found on PubMed as of 07/28/2026.

Mechanism of Action

Oleamide (cis-9-octadecenoamide) is a primary fatty acid amide (a fat molecule capped with an amide group) that the body produces and that also enters the body from food and plastics. It is best understood not as a single-target drug but as a promiscuous signaling lipid that touches several systems at once.

Endocannabinoid system: Oleamide is a substrate for, and inhibitor of, fatty acid amide hydrolase (FAAH, the enzyme that breaks down the body’s cannabis-like signaling fats). By competing for FAAH, oleamide slows the breakdown of anandamide (a natural cannabinoid), raising its levels — the so-called “entourage effect.” Oleamide also acts as a direct, if modest, agonist at the CB1 cannabinoid receptor (a brain receptor also engaged by cannabis) and can engage CB2 receptors (the mainly immune-associated cannabinoid receptor). Blocking CB1 abolishes much of oleamide’s sleep effect in animals.
Serotonin (5-HT) signaling: Oleamide allosterically potentiates several serotonin receptor subtypes, increasing chloride currents through 5-HT2A and 5-HT2C receptors at low nanomolar concentrations and modulating 5-HT7 and 5-HT1A responses. This serotonergic action is linked to both its sleep and mood effects, though at least one hippocampal study found no serotonergic modulation, indicating brain-region specificity.
GABA-A receptors: Oleamide potentiates benzodiazepine-sensitive GABA-A receptor activity (the receptor for the brain’s main calming neurotransmitter, gamma-aminobutyric acid), contributing to its calming and sleep-promoting profile.
Other targets: Oleamide activates TRPV1 (a heat- and capsaicin-sensitive ion channel), interacts with voltage-gated sodium channels, inhibits gap-junction communication between cells, and activates PPARα (peroxisome proliferator-activated receptor alpha, a fat-sensing gene regulator), the last linked to promotion of new hippocampal neurons.
Competing mechanistic views: A central debate is whether oleamide acts mainly directly (binding CB1, serotonin, and GABA-A receptors itself) or indirectly (chiefly by inhibiting FAAH and thereby raising anandamide). Evidence supports both, and the balance likely depends on dose, tissue, and species; some effects (glioblastoma cell death, certain vascular responses) are explicitly cannabinoid-receptor-independent.

Key pharmacological properties: Oleamide is short-lived, being rapidly hydrolyzed by FAAH to oleic acid and ammonia; its selectivity is low (multi-target). It is lipophilic, crosses the blood-brain barrier, and in the circulation travels bound to albumin, entering tissues partly via the fat transporter CD36; oral oleamide is absorbed largely through the portal vein rather than lymph. Endogenous plasma levels are roughly 30 nM, rising several-fold after oral dosing in animals. It is not primarily a cytochrome P450 (CYP, the liver’s main drug-metabolizing enzyme family) substrate, though it can weakly modulate some CYP enzymes.

Historical Context & Evolution

Original identity: Oleamide is not a designed drug but an endogenous molecule. It was chemically characterized in 1995 by Cravatt and colleagues, who isolated it from the cerebrospinal fluid (the fluid bathing the brain and spinal cord) of sleep-deprived cats and showed it accumulated with wakefulness and induced sleep.
Why it entered health optimization: Because oleamide is a natural, sleep-linked lipid that appears to promote physiological sleep rather than force sedation, it attracted interest as a template for gentler sleep aids and, more recently, as a direct supplement. It is also found in foods and traditional remedies — jujube (Ziziphus) fruit used in Chinese practice for millennia, Camembert-style cheese fermented by Penicillium camemberti, Moringa oleifera leaves, and Rosa rugosa roots — which reinforced its framing as a “natural” sleep and cognition compound.
What the early research actually showed: The foundational work demonstrated a reproducible, dose-related sleep-inducing effect in rodents and identified FAAH as the enzyme controlling oleamide levels. These findings were not overturned; rather, subsequent work broadened oleamide from a single “sleep factor” into a multi-target signaling lipid with serotonergic, cannabinoid, GABAergic, vascular, and anti-inflammatory actions.
Evolution of opinion: Interest shifted somewhat from oleamide itself toward FAAH inhibitors as drugs, and awareness grew that oleamide is also a ubiquitous industrial slip agent that leaches from plastics — complicating both its measurement and its image. The current standing is open: oleamide is an intriguing, broadly active lipid whose human evidence remains thin, and neither enthusiasm nor dismissal is settled.

Expected Benefits

The benefit profile below was cross-checked against PubMed and clinical/expert sources. A central caveat frames every entry: for a health- and longevity-focused adult, almost all evidence for oleamide is preclinical (cell and rodent studies), with a single small human trial. Benefits are therefore graded conservatively.

Low 🟩

Sleep Onset & Quality Support

Oleamide is the archetypal endogenous “sleep-inducing lipid”: in rodents it shortens the time to fall asleep and increases total and non-REM (non–rapid-eye-movement) sleep, acting through combined GABA-A potentiation and cannabinoid signaling. In the one human trial (healthy older Japanese adults, 60 µg/day for 12 weeks), the oleamide group improved within-group on subjective sleep quality and sleep latency, although the overall sleep-index difference versus placebo was not statistically significant. For this audience the realistic expectation is a mild sleep-onset and sleep-quality aid, not a potent hypnotic, and the human signal is preliminary.

Magnitude: Human trial (60 µg/day, 12 weeks): significant within-group improvement in subjective sleep quality and sleep latency subscales; no significant between-group difference on the total sleep-quality score.

Cognitive Function & Memory Support

The same randomized, placebo-controlled human trial reported that oleamide improved a memory performance index and both immediate and delayed free-recall subscales relative to placebo, alongside a small favorable shift in serum brain-derived neurotrophic factor (BDNF, a protein that supports neuron growth and survival). Rodent work aligns: neonatal oleamide supplementation improved later learning and memory by boosting hippocampal neurogenesis and synaptic markers, and oleamide upregulates doublecortin (a marker of new neurons) via PPARα. The effect is plausible and mechanistically supported but rests on one small, industry-conducted human study.

Magnitude: Memory Performance Index and immediate/delayed free-recall significantly improved versus placebo (reported p < 0.001) at 60 µg/day over 12 weeks in ~58 older adults.

Speculative 🟨

Anxiety & Mood Regulation

Across rodent models oleamide shows anxiolytic and antidepressant-like effects — reducing immobility in the forced-swim test and reversing anhedonia (loss of the ability to feel pleasure) in a chronic mild-stress model — likely through combined serotonergic and cannabinoid actions, with a proteomic study identifying stress-related protein changes. No controlled human data exist; the basis is mechanistic and animal-behavioral only, so any mood benefit for a human user is unproven.

Neuroprotection & Neurogenesis

In cell and rodent models oleamide protects neurons against excitotoxic (nerve-damaging overexcitation) and mitochondrial injury (partly via CB1/CB2 receptors), reduces amyloid-beta-driven oxidative stress while restoring acetylcholine, and alleviates postoperative cognitive dysfunction through a CB2-receptor pathway. These findings suggest a longevity-relevant brain-protective role, but all evidence is preclinical and no human neuroprotection has been demonstrated.

Anti-Inflammatory & Immune Modulation ⚠️ Conflicted

Oleamide suppresses inflammatory responses in some models — reducing microglial activation and easing paw edema in rats — yet in primary human macrophages it did the opposite, driving a pro-inflammatory M1 phenotype and interleukin-1β release via the NLRP3 inflammasome (an immune-sensor complex). The direction of oleamide’s immune effect therefore appears context- and cell-type-dependent, and no net anti-inflammatory benefit can be claimed for humans; this conflict is why the item is flagged.

Metabolic Health & Muscle Preservation

Dietary oleamide reduced fat gain, improved glucose tolerance, and preserved skeletal-muscle mass in sedentary (small-cage) mice, the latter through the Akt/mTOR growth pathway and restored autophagy. This hints at a role against inactivity-related decline relevant to longevity, but the data are entirely rodent and used doses far above the human supplement range.

Vascular Function & Blood Pressure

Oleamide is a potent vasodilator in rat vessels and lowers blood pressure through endothelium-derived signals and TRPV1/CB1 involvement. While potentially favorable for vascular aging, this is animal-only and cuts both ways — the same effect is also listed as a potential hypotension risk.

Anti-Cancer Activity

Oleamide triggers death of glioblastoma cell lines, in part through a cannabinoid-receptor-independent mechanism and, in recent work, mitochondrial and PPAR-γ (a related fat-sensing gene regulator) modulation. This is early in-vitro signal only, with no animal tumor or human data, and is far from a usable benefit.

Benefit-Modifying Factors

FAAH genetic variants: A common loss-of-function polymorphism in the FAAH gene (C385A) reduces breakdown of fatty acid amides and raises endogenous cannabinoid tone. Carriers may in principle respond differently to oleamide, since FAAH governs its clearance, though this has not been directly tested for oleamide.
Baseline sleep and biomarker status: Individuals with poor baseline sleep quality or measurable cognitive decline (as in the human trial population) appear most likely to notice benefit; well-rested people with intact cognition may perceive little. Baseline BDNF and inflammatory tone may also shape response.
Sex-based differences: Rodent studies report sex differences in oleamide’s behavioral effects, with distinct responses between male and female mice in mood-related tests. Whether this translates to humans is unknown.
Pre-existing conditions: Existing anxiety, insomnia, or early cognitive impairment define the populations where signals have appeared; conversely, conditions affecting the endocannabinoid system or liver metabolism could alter response.
Age: The only human evidence is in adults aged roughly 50–75, the older end of this audience; benefits in younger, healthy adults are untested and cannot be assumed.

Potential Risks & Side Effects

Human safety data for oleamide are very limited: the single 12-week trial reported no treatment-related adverse events at a microgram-level dose. Risks below are therefore drawn largely from mechanism, animal work, and the pharmacology of related sedating compounds, and most are graded low or speculative because they are not established in humans at supplement doses.

Low 🟥

Daytime Drowsiness & Sedation

As a sleep-promoting compound acting through GABA-A and cannabinoid pathways, oleamide can plausibly cause drowsiness, and residual next-day grogginess is the most commonly anticipated effect when it is taken for sleep. The severity is expected to be mild and dose- and timing-dependent, but it is the most predictable consequence of its mechanism and argues against daytime use or use before driving.

Magnitude: Not quantified in available studies.

Additive Sedation with Central Depressants

Oleamide potentiates benzodiazepine-sensitive GABA-A receptors and, in rodents, acted synergistically with a sub-threshold dose of a benzodiazepine to shorten sleep latency. Combined with alcohol, benzodiazepines, or other sedatives, additive central-nervous-system depression is a realistic concern even if oleamide alone is mild.

Magnitude: Not quantified in available studies.

Speculative 🟨

Blood Pressure Lowering / Hypotension

Oleamide is a potent vasodilator and lowered blood pressure in rats. At high exposures, or combined with antihypertensives or other blood-pressure-lowering agents, a theoretical risk of excessive blood-pressure drop or lightheadedness exists. No human cardiovascular effects have been reported, and supplement doses are far lower than those used in animals.

Pro-Inflammatory Immune Shifts ⚠️ Conflicted

In primary human macrophages, oleamide pushed cells toward a pro-inflammatory M1 state and activated the NLRP3 inflammasome, the opposite of the anti-inflammatory effects seen in other models. Whether this matters for a person taking oral oleamide is unknown, but it raises a theoretical concern for those with inflammatory or autoimmune conditions; the conflicting evidence is why it is flagged.

Drug-Metabolizing Enzyme Modulation

In rats, oleamide downregulated several liver cytochrome P450 enzymes (CYP1A2, CYP2B, CYP2C11) and weakly inhibited others, which could in theory alter the clearance of co-administered medications. Reassuringly, in human enzyme systems oleamide did not meaningfully inhibit major CYPs or activate the nuclear receptors that regulate them, so the human interaction risk appears low but is not fully characterized.

Contaminant & Purity Concerns

Oleamide is a widely used industrial slip agent that leaches from plastics, syringes, and packaging into food, drink, and medicines, meaning unintended exposure is common and product purity varies. A poorly characterized supplement could carry industrial-grade material or contaminants, and the same property complicates laboratory measurement of oleamide.

Unknown Long-Term & Reproductive Safety

There are no long-term human safety studies, and no data in pregnancy, breastfeeding, or children. Given oleamide’s broad receptor activity and presence in breast milk, the absence of safety data — rather than any specific documented harm — is itself the risk for these groups.

Risk-Modifying Factors

FAAH genetic variants: Because FAAH clears oleamide, carriers of reduced-function FAAH variants could accumulate higher levels and experience stronger sedative or cannabinoid-like effects; this is mechanistically plausible but untested for oleamide specifically.
Baseline blood pressure: Individuals who already run low blood pressure, or who take antihypertensive medication, are the group in whom oleamide’s vasodilator tendency could theoretically matter most.
Sex-based differences: Rodent data show sex-dependent behavioral responses to oleamide, so side-effect intensity may differ between men and women, though human data are absent.
Pre-existing conditions: Those with inflammatory or autoimmune disease (given the pro-inflammatory macrophage signal), significant liver disease (given CYP modulation), or on sedatives warrant the most caution.
Age: Older adults — the only studied human group — may be both more likely to benefit and more sensitive to sedation and blood-pressure effects, given generally slower drug clearance and higher baseline medication use.

Key Interactions & Contraindications

Sedatives and hypnotics (prescription): Benzodiazepines (diazepam, lorazepam, alprazolam), “Z-drugs” (zolpidem, eszopiclone), and barbiturates (phenobarbital, secobarbital) — caution to avoid; additive central-nervous-system depression and excessive sedation. Mitigation: the combination is avoided; where a sleep medication is already used, oleamide is not layered on top.
Over-the-counter sedating agents: Sedating antihistamines (diphenhydramine, doxylamine) and OTC “PM” sleep products — caution; additive drowsiness and next-day impairment. Mitigation: same-night stacking is avoided.
Supplement interactions (additive sedation): Other sleep and calming supplements that act on overlapping calming pathways — melatonin, valerian, kava, magnesium, L-theanine, phenibut, and GABA — may add to oleamide’s sedative effect. Caution; consequence is deeper sedation or morning grogginess. Mitigation: agents are introduced one at a time, with doses separated or reduced.
Cannabis and cannabinoids: Because oleamide engages CB1/CB2 receptors and competes at FAAH, combining it with cannabis, THC (tetrahydrocannabinol), or high-dose CBD (cannabidiol, itself a FAAH-pathway modulator) could potentiate cannabinoid effects. Caution; monitor for enhanced sedation or psychoactivity.
Blood-pressure-lowering agents: Antihypertensives (e.g., lisinopril, amlodipine, losartan) and other vasodilating supplements (e.g., high-dose nitrate/beetroot, arginine) — monitor; theoretical additive blood-pressure lowering and lightheadedness.
CYP-sensitive medications: Drugs with narrow therapeutic margins metabolized by cytochrome P450 enzymes (e.g., warfarin, phenytoin, theophylline) — monitor on theoretical grounds only, since human CYP inhibition by oleamide appears minimal.
Populations who should avoid oleamide: Pregnant or breastfeeding women and children (no safety data); people already taking prescription sedatives or with a history of sedative misuse; and anyone before driving or operating machinery on the day of use. Those with significant liver impairment or hypotension should approach with added caution.

Risk Mitigation Strategies

Bedtime-only, low starting dose: Starting at the low end (around 100 mg, one capsule) taken only at night directly limits daytime drowsiness and next-day grogginess, the most predictable adverse effect, and reveals individual sensitivity before any increase.
Avoid stacking with depressants: Keeping oleamide separate from alcohol, prescription sedatives, sedating antihistamines, and multiple calming supplements on the same night prevents additive central-nervous-system depression, the main clinically relevant risk.
Separate from driving and demanding tasks: Confining oleamide to occasions when a full night’s sleep will follow and no driving or machinery operation is planned for at least 8 hours mitigates sedation-related accident risk.
Prioritize third-party-tested products: Oleamide verified by third-party laboratory testing for identity and purity mitigates the contaminant risk arising from its industrial use as a plastic slip agent.
Medication and condition review: Reconciling oleamide against current medications (especially sedatives, antihypertensives, and narrow-margin drugs) and conditions (pregnancy, liver disease, hypotension, autoimmune disease) before use mitigates interaction and vulnerable-population risks.
Time-limited trial with reassessment: Rather than open-ended nightly use, a defined trial (for example 4–8 weeks) with reassessment of benefit addresses the uncharacterized long-term human safety; use is discontinued if no clear benefit emerges.

Therapeutic Protocol

Because oleamide has no clinical dosing guidelines and only one low-dose human trial, no authoritative “standard of care” exists. The protocol below reflects how the compound is actually sold and used, and is presented as description, not instruction.

Common supplement protocol: Retail oleamide (notably from Nootropics Depot, the main vendor) is offered at 100 mg per capsule, taken once at night with food, with a stated range of 1–2 times daily; users typically take it 30–60 minutes before bed. This is the de-facto popularized approach in the nootropics community rather than a clinically validated regimen.
Research (food-derived) approach: The only human trial used a far smaller dose — 60 µg/day derived from a Penicillium camemberti (white-mold) milk culture — over 12 weeks for cognition and sleep. This illustrates a competing “low-dose, food-matrix” approach that differs from the higher-milligram supplement approach by more than a thousandfold, and neither has been shown superior.
Best time of day: Evening/pre-sleep dosing is near-universal, matching oleamide’s sleep-promoting mechanism and minimizing daytime sedation.
Half-life considerations: Oleamide is rapidly hydrolyzed by FAAH and is short-acting, which is consistent with once-nightly bedtime dosing rather than daytime maintenance dosing.
Single vs split dosing: Given the short half-life and sleep-directed purpose, a single bedtime dose is typical; splitting doses is not standard and would risk daytime drowsiness.
Genetic considerations: No pharmacogenetic dosing guidance exists, but FAAH-variant carriers (who clear fatty acid amides more slowly) may in theory need less; this is untested.
Sex-based considerations: Rodent data suggest sex differences in response, but no human sex-specific dosing is established.
Age considerations: The only human data are in adults ~50–75; older users may prefer the lowest effective dose given greater sedation sensitivity and polypharmacy.
Baseline biomarker considerations: Poorer baseline sleep or cognition predicted response in the available evidence, so these baselines are reasonable factors in deciding whether a trial is worthwhile.
Pre-existing conditions: Presence of sedative use, hypotension, or liver disease should lower the threshold for caution and favor the smallest dose.

Discontinuation & Cycling

Lifelong vs short-term: Oleamide is best regarded as a short-term or trial-based aid rather than a lifelong commitment, because long-term human safety is uncharacterized and benefit beyond a few months is unstudied.
Withdrawal effects: No withdrawal syndrome has been documented. As an endogenous, short-acting molecule it is not expected to produce dependence, but rebound of the original sleep or mood complaint on stopping is possible.
Tapering: No taper is described or expected to be necessary given the lack of documented physical dependence; abrupt discontinuation appears reasonable.
Cycling: No evidence supports or refutes cycling for sustained efficacy. Tolerance has not been formally studied; some users cycle sleep aids empirically to preserve effect, but this is not established for oleamide.
Reassessment cadence: A practical approach is a defined trial (for example 4–8 weeks) followed by a decision to continue, pause, or stop based on clear benefit, rather than indefinite nightly use.

Sourcing and Quality

Purity and third-party testing: Because oleamide is manufactured at industrial scale as a plastic slip agent, supplement-grade material should be explicitly intended for human consumption and verified by third-party laboratory testing for identity and purity; certificates of analysis are the key thing to look for.
Form and dose transparency: Oleamide is sold as capsules and bulk powder, typically standardized to 100 mg; products should clearly state dose per serving and be free of undisclosed fillers. Powder allows finer dose control but demands accurate weighing.
Reputable sources: Nootropics Depot is the principal retailer publishing third-party test data for oleamide; food-derived exposure also occurs naturally via aged cheeses, jujube, and Moringa, though these are not standardized delivery routes.
Isomer and freshness considerations: The biologically active form is the cis isomer (cis-9-octadecenoamide); the trans isomer lacks much of the activity, so genuine cis-oleamide matters. As an unsaturated lipid it is susceptible to oxidation and benefits from cool, dark storage.
Distinguishing supplement from contaminant grade: Buyers should ensure the product is a dedicated dietary supplement rather than a repackaged industrial chemical, since the same molecule is sold cheaply for plastics manufacturing.

Practical Considerations

Time to effect: Sleep effects are intended to be same-night (taken 30–60 minutes before bed); in the human cognition trial, memory and sleep-quality changes were measured after 12 weeks, so cognitive benefits, if real, accrue over weeks rather than immediately.
Common pitfalls: Taking oleamide too late (leading to next-morning grogginess), stacking it with alcohol or other sedatives, expecting a potent hypnotic effect, dosing during the day, and buying non-tested or industrial-grade material are the most common mistakes.
Regulatory status: Oleamide is sold as a dietary supplement / research compound and is not an approved drug for any indication; its use for sleep or cognition is entirely off-label and unregulated as to efficacy. It is also listed in food-contact regulations as a permitted plastic additive.
Cost and accessibility: Oleamide is inexpensive and easy to obtain online (roughly $20 for a one-to-two-month supply), so cost and access are not meaningful barriers; the limiting factor is evidence, not availability.
Measurement caveat: Because oleamide contaminates labware and plasticware, do-it-yourself or lab measurement of oleamide levels is unreliable, and users cannot easily confirm systemic exposure.

Interaction with Foundational Habits

Sleep: Direct, potentiating. Oleamide’s core mechanism is sleep promotion via GABA-A and cannabinoid signaling, so it directly reinforces good sleep and is best timed to the wind-down routine; the practical consideration is to avoid late dosing that pushes sedation into the morning and to treat it as an adjunct to, not a replacement for, sleep hygiene.
Nutrition: Indirect. Oleamide is a fat-soluble molecule absorbed via the portal vein bound to albumin and is present in foods such as aged cheese, jujube, and Moringa; taking it with a meal (as vendors suggest) aligns with fat-based absorption. No specific diet is required, and no nutrient depletion is documented.
Exercise: Indirect, possibly supportive. In sedentary mice, dietary oleamide preserved muscle and reduced fat gain through growth-signaling pathways, hinting at synergy with an active lifestyle; however, this is rodent-only, and its sedative timing means it should be kept to the evening, away from training.
Stress management: Direct. Through serotonergic and cannabinoid actions oleamide showed anxiolytic and antidepressant-like effects in animals and may complement stress-reduction practices; the proposed mechanism is dampened stress-axis and enhanced calming signaling, though human confirmation is lacking.

Monitoring Protocol & Defining Success

Formal laboratory monitoring is not established for oleamide, and at typical low doses intensive lab surveillance is not warranted. Baseline testing is therefore optional and aimed mainly at safety context and at capturing the sleep, mood, and cognitive changes that define success for this compound. Where labs are considered, they are general safety and response markers rather than oleamide-specific tests.

Baseline assessment, when done, is best captured before starting: a subjective sleep and mood baseline plus, for those with relevant risk factors, the safety labs below. Ongoing monitoring is light — for example a review at 4 weeks and again at 8–12 weeks — and is driven mostly by how a person feels rather than by repeat blood work; the labs below need checking only every 6–12 months or if a specific concern (e.g., new medication, symptoms) arises.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT / AST	ALT ~10–26 U/L; AST ~10–26 U/L	Screen liver health given oleamide’s modulation of liver enzymes in animals	ALT and AST are liver enzymes; conventional upper limits (~40–50 U/L) are looser than these functional targets; fasting preferred; only relevant for prolonged use or existing liver concern
Blood pressure	~110–125 / 70–80 mmHg	Context for oleamide’s vasodilator/blood-pressure-lowering signal	Not a blood test; measure seated after rest; more relevant for those already hypotensive or on antihypertensives
Fasting glucose / HbA1c	Glucose ~75–85 mg/dL; HbA1c <5.4%	Optional metabolic context given rodent metabolic effects	HbA1c is glycated hemoglobin (reflecting average blood sugar over roughly 3 months); standard reference calls HbA1c <5.7% normal; measure fasting; low priority for short-term sleep use
hs-CRP	<1.0 mg/L	Optional check given oleamide’s conflicting immune effects	hs-CRP is high-sensitivity C-reactive protein, a general inflammation marker; avoid testing during acute illness; interpret cautiously

Qualitative markers are the primary way to judge success with oleamide:

Time to fall asleep and number of night-time awakenings
Subjective sleep depth and morning refreshment
Presence or absence of next-day grogginess or drowsiness
Daytime mood, calm, and stress resilience
Memory and cognitive clarity over weeks of use

Emerging Research

A ClinicalTrials.gov search returned no registered interventional trials of oleamide as of this review, so “emerging research” here is dominated by preclinical work and medicinal-chemistry programs, presented in both directions — findings that could strengthen and findings that could weaken the case for oleamide.

No registered human trials: A ClinicalTrials.gov search for oleamide as an intervention returned zero studies, underscoring that the field’s next needed step is confirmatory human trials rather than further mechanism papers. The single existing human study (Sasaki et al., 2024) is small, industry-run, and awaits independent replication.
Serotonin-receptor drug discovery (strengthening): Medicinal chemists have built brain-penetrant oleamide analogues that positively modulate 5-HT2C and dual 5-HT2C/5-HT2A serotonin receptors, a program aimed at mood, appetite, and substance-use disorders (Chen et al., 2023, DOI 10.1021/acs.jmedchem.3c00908). This validates oleamide as a pharmacological template even as it moves beyond the parent molecule.
Neurogenesis and Alzheimer’s directions (strengthening): Work showing oleamide upregulates the new-neuron marker doublecortin via PPARα (Roy et al., 2021) and protects against amyloid-beta toxicity (Park et al., 2025) points to possible repurposing for cognitive aging, pending in-vivo and human confirmation.
Oncology signal (strengthening, early): A 2026 study reports anti-proliferative effects of oleamide in glioblastoma cell lines involving mitochondrial and PPAR-γ modulation (Torres-Román et al., 2026), an early direction with no animal-tumor or human data yet.
Pro-inflammatory immune signal (weakening / cautionary): Evidence that oleamide can drive pro-inflammatory M1 macrophage polarization and NLRP3-inflammasome activation in human cells (Wisitpongpun et al., 2022) complicates the “anti-inflammatory” narrative and could weaken the safety case if confirmed in vivo.
Bioavailability and delivery challenge (weakening): Absorption and metabolism work shows oleamide is taken up via CD36 and rapidly degraded by FAAH in the gut and tissues (Kobayashi et al., 2022), raising the unresolved question of whether oral oleamide reaches the brain at meaningful levels — a key uncertainty for any human benefit.
Future research areas: The decisive open questions are whether oral supplement doses produce clinically meaningful sleep or cognitive effects in independent human trials, what the correct dose is (the microgram trial dose versus the milligram supplement dose differ enormously), and whether the conflicting immune effects matter in vivo.

Conclusion

Oleamide is a fat-based molecule the body makes for itself, best known as one of the brain’s own sleep signals. It works by gently nudging several calming and mood-related systems at once rather than hitting a single target, which makes it biologically interesting but also hard to characterize. In laboratory and animal studies it reliably promotes sleep and shows a wide spread of additional signals — calmer mood, protection of brain cells, support for memory, and effects on metabolism and blood vessels.

The gap between this rich laboratory picture and real human evidence is the central point. Only one small, short human trial exists, and while it hinted at better memory and sleep-related measures in older adults, it was modest, industry-run, and not yet repeated. Most claims therefore rest on cells and rodents, some findings openly conflict with one another, and long-term safety in people is simply unknown. Practical concerns include next-day drowsiness, additive effects with other sedatives, and the fact that the same compound is an industrial plastic additive, making purity important.

Oleamide is inexpensive and readily available, so the limiting factor is evidence, not access. For a health- and longevity-minded reader, it sits as a low-cost, low-dose, genuinely intriguing compound whose promise remains largely unproven, and whose most honest description today is “early and uncertain.”

Top - Benefits - Risks - Protocol

Oleamide for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Low 🟩

Sleep Onset & Quality Support

Cognitive Function & Memory Support

Speculative 🟨

Anxiety & Mood Regulation

Neuroprotection & Neurogenesis

Anti-Inflammatory & Immune Modulation ⚠️ Conflicted

Metabolic Health & Muscle Preservation

Vascular Function & Blood Pressure

Anti-Cancer Activity

Benefit-Modifying Factors

Potential Risks & Side Effects

Low 🟥

Daytime Drowsiness & Sedation

Additive Sedation with Central Depressants

Speculative 🟨

Blood Pressure Lowering / Hypotension

Pro-Inflammatory Immune Shifts ⚠️ Conflicted

Drug-Metabolizing Enzyme Modulation

Contaminant & Purity Concerns

Unknown Long-Term & Reproductive Safety

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion